The FDA also accepted Sobi’s New Drug Application (NDA) for avatrombopag for oral suspension. Avatrombopag for oral suspension is a capsule where its granules are sprinkled onto a soft food or liquid ...

The US Food and Drug Administration (FDA) has accepted Sobi North America’s avatrombopag (DOPTELET) supplemental new drug ...

Blood disorders are a group of conditions that affect the production, function, or structure of blood cells, leading to ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for avatrombopag for the treatment of thrombocytopenia in pediatric patients aged 1 year and older with ...

The oral BTK inhibitor rilzabrutinib led to rapid and durable platelet responses, reduced bleeding, and improved fatigue in ...

Positive results from the pivotal LUNA 3 phase 3 study of rilzabrutinib in adults with persistent or chronic immune thrombocytopenia (ITP), a rare immune-mediated disease, reinforce the efficacy and ...

ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITPPivotal phase 3 data ...

USA: Findings from the PINES trial suggest that eltrombopag (Promacta) may offer improved outcomes for children with newly ...

Blood disorders affect millions worldwide—an estimated 5% of the global population suffers from conditions like anemia, and others. Anemia is a silent epidemic, with over 2 billion people ...

SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet ...